Company intelligence / Profile preview

Amolyt Pharma

Ownership: Private
Development stage: Other

Overview

Eneboparatide (AZP-3601) has shown positive Phase 2 results for hypoparathyroidism, maintaining mean serum calcium within target range and allowing discontinuation of oral supplements in 93% of patients. The Phase 3 Calypso trial began in May 2023. AZP-3813 entered Phase 1 trials in June 2023 for acromegaly, with results expected in Q1 2024.

Therapeutic areas: Endocrinology
Modalities: Therapeutic peptides
Industry: Biotech

Beyond the preview

Go deeper on Amolyt Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amolyt Pharma.